aceRandomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix
Background Antibodies against the SARS-CoV-2 spike receptor-binding domain provided effective COVID-19 treatment until resistant variants emerged. GB-0669 is a half-life-extended monoclonal antibody optimized using artificial intelligence. It targets the conserved spike S2 stem helix, a region subject to limited selective pressure from antibody responses induced by natural infection or vaccination. Methods Pre-clinical safety studies were conducted in cynomolgus monkeys. In the first-in-human trial, healthy adul…
"Novel Coronavirus SARS-CoV-2–Colorized scanning electron micrograph of a VERO E6 cell (blue) heavily infected with SARS-COV-2 virus particles (orange), isolated from a patient sample. Original image sourced from US Government department: The Nationa" by Free Public Domain Illustrations by rawpixel is licensed under CC BY 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by/2.0/.
Researchers conducted pre-clinical studies in cynomolgus monkeys and a first-in-human trial of GB-0669, described as a half-life-extended monoclonal antibody optimized using artificial intelligence targeting the conserved SARS-CoV-2 spike S2 stem helix. Fifty-one healthy adults aged 18-55 received single intravenous doses from 100 to 2400 mg or placebo and were followed for 43 weeks for safety, pharmacokinetics, and serum live virus neutralization.
By the July 2026 publication date, the antibody had demonstrated tolerability without dose-limiting toxicities, a 54-day half-life, and dose-dependent neutralization at 600 and 1200 mg, with in vitro data suggesting improved profiles when combined with remdesivir, nirmatrelvir, and molnupiravir. The findings support advancing to Phase 2 testing at 1200 mg for COVID-19 treatment in immunocompromised individuals, but efficacy in patients remains unproven and combination benefits are still in vitro.
- GB-0669 targets the conserved spike S2 stem helix, described as a region subject to limited selective pressure from antibody responses induced by natural infection or vaccination.
- First-in-human design: 51 healthy adults aged 18-55 in five ascending single intravenous dose cohorts from 100 to 2400 mg, monitored for 43 weeks for safety, pharmacokinetics and serum live virus neutralization.
- Pharmacokinetics showed dose-proportionality up to 2400 mg with 54-day half-life; dose-dependent increases in neutralization at 600 and 1200 mg with separation from placebo.
- In vitro work showed improved neutralization profiles of GB-0669 in combination with remdesivir, nirmatrelvir, and molnupiravir.
AI-optimized monoclonal antibody GB-0669 was safe and well-tolerated in healthy adults with dose-proportional pharmacokinetics and a 54-day half-life and dose-dependent serum live virus neutralization.
The rundown
Pre-clinical safety studies in cynomolgus monkeys revealed no safety concerns, leading to a first-in-human randomized, double-blind, placebo-controlled trial with five ascending single intravenous doses of 100, 300, 600, 1200, and 2400 mg in 51 participants.
Clinical results showed no dose-limiting toxicities, mild Grade 1 or 2 adverse reactions only, dose-proportionality up to 2400 mg, and an estimated neutralizing index supporting therapeutic efficacy for two weeks post-administration, with authors concluding data support a 1200 mg Phase 2 trial in immunocompromised individuals and potential combination benefit with antivirals.
Sources
- Peer-reviewedThe Journal of Infectious Diseases2026-07-14
How should this claim be treated?
The debate